Tilray shares jump as stock buying pressure builds

Traders Union
All News
Financial News
Tilray surges 3.67% to $5.65 today

Highlights

Tilray reported an 11% year-over-year revenue increase and 6% gross profit growth in the third fiscal quarter, maintaining adjusted EBITDA guidance of $62 million to $72 million for FY 2026.
The company is expanding international and segment presence via Tilray Medical's advocacy at Cannabis Europa London 2026 and launching a major BrewDog beverage campaign in the UK.
Technicals show short-term stabilization above support near $5.32, but weak overall indicators suggest prolonged sideways or downward trading within a $5.32 to $5.87 range.

Expansion in medical cannabis and sports marketing as U.S. regulatory shifts weigh

Tilray continues to expand its presence in the medical cannabis space, highlighted by its participation in Cannabis Europa London 2026 through the Tilray Medical division as it advocates for advancing medical cannabis policy and patient access globally. Third fiscal quarter results show an 11% year-over-year revenue increase and a 6% gain in gross profit, with management maintaining guidance for adjusted EBITDA between $62 million and $72 million for the fiscal year ending June 30, 2026. The company is also promoting its beverage segment with a large-scale UK marketing campaign for its BrewDog brand during major summer football events. Ongoing developments in U.S. cannabis regulation, including the prospect of rescheduling marijuana, remain a key factor for Tilray's longer-term growth prospects.

Anton Kharitonov, expert at Traders Union, notes that Tilray’s technical setup remains fragile. He sees temporary stabilization above the 20-day moving average, but bearish signals dominate the medium and long-term picture. Weak trend strength and mixed oscillators add uncertainty, while overbought short-term signals raise red flags for new buyers. Earnings growth and marketing efforts have not altered the stock’s vulnerability to further downside. "Until TLRY overcomes resistance at $5.87 and proves sustained buying, I consider any rally as a chance for cautious risk management."

Viktoras Karapetjanc, expert at Traders Union, focuses on Tilray's robust revenue growth and expanding medical cannabis footprint. He sees the company strengthening its global profile through initiatives like Cannabis Europa London and innovative marketing in the UK. Continued regulatory momentum in the U.S. could be a game-changer for long-term expansion. The bullish structure remains intact as management reaffirms forward guidance and seizes new opportunities. "With tailwinds from medical adoption and U.S. policy shifts, I expect further upside potential for TLRY this year."

Parshwa Turakhiya, analyst, observes a tug-of-war between short-term buying appetite and stubborn bearish momentum in Tilray. The flat open and intraday strength show traders' willingness to test resistance, but volatility and overbought short-term oscillators limit conviction. He believes mixed signals require tactical patience, with focus on the $5.32 to $5.87 range. "If bulls can defend current levels, I see short-term trading setups for active participants, but the broader trend urges caution."

Mixed momentum signals as short-term buyers battle bearish trend

Tilray trades just above the 20-day moving average ($5.64) but remains well below the 50-day ($6.29) and 200-day ($9.69) moving averages. This setup signals short-term stabilization with medium- and long-term trends still under bearish pressure, while the nearest significant resistance is set by the 50-day average and support emerges near the Ichimoku Kijun level at $7.22. Momentum signals are mixed: MACD on the daily timeframe points to strong bearish momentum, but the Average Directional Index (ADX) is weak and neutral, indicating a lack of clear trend strength. The Relative Strength Index (RSI) stands at 40.96, and the Commodity Channel Index (CCI) is neutral; both are shy of oversold levels, while the Stochastic RSI indicates overbought conditions across most short timeframes. Bull/Bear Power (BBP) shows buyers currently dominate intraday momentum, and the daily move is up by $0.20 or 3.67%. The stock opened nearly flat and is trading near the session high, with intraday volatility at 4.04%. Strong upward tone is present after the open. However, the divergence between overbought oscillators and bearish daily momentum suggests a tug-of-war between short-term optimism and persistent selling pressure.

Earlier, analysts noted that Tilray was contending with persistent bearish momentum despite its efforts to expand operations internationally. The latest developments—showing improved revenue, upbeat intraday sentiment, and ongoing regulatory tailwinds—introduce a more balanced risk profile, with investors now advised to track price action around the $5.87 resistance for signs of a sustained trend shift.

Source of Data: TLRY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.